It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.
本发明旨在提供一种对
精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说,本发明旨在提供一种具有治疗或预防抑郁症、焦虑症、阿尔茨海默病、帕
金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗塞、脑缺血、脑
水肿、头部损伤、炎症、免疫系统疾病、脱发等作用的药物。经过深入研究,发现了一种新型的1,3-二氢
吲哚-2-酮化合物和一种与杂环芳香族环融合的
吡咯烷-2-酮化合物,它们是
精氨酸加压素V1b受体高度选择性的拮抗剂,具有高代谢稳定性、良好的脑穿透力和高血浆浓度,从而实现了上述目标。